SPG302   Click here for help

GtoPdb Ligand ID: 13262

Synonyms: Phenylbenzothiazole-PEG4-OH | SPG-302
Compound class: Synthetic organic
Comment: SPG302 induces synaptogenic regenerative actions in neural tissues [1-2]. Mechanistically SPG302 targets a regulator of the F-actin-based cytoskeleton to increase dendritic spine density and promote the formation of new synapses. It increases the density of axospinous glutamatergic synapses in Alzheimer's disease model mice.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 13
Topological polar surface area 94.81
Molecular weight 403.49
XLogP 0.25
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C1=CC=C2C(=C1)N=C(C3=CC=C(C=C3)OCCOCCOCCOCCO)S2
Isomeric SMILES C1=CC=C2C(=C1)N=C(S2)C3=CC=C(C=C3)OCCOCCOCCOCCO
InChI InChI=1S/C21H25NO5S/c23-9-10-24-11-12-25-13-14-26-15-16-27-18-7-5-17(6-8-18)21-22-19-3-1-2-4-20(19)28-21/h1-8,23H,9-16H2
InChI Key XSAIPEACQNRHOL-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Spinogenix are developing SPG302 as a treatment for amyotrophic lateral sclerosis (ALS). The FDA designated SPG302 as an orphan drug for ALS in April 2021.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05882695 Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SPG302 in Healthy Volunteers and ALS Participants Phase 1 Interventional Spinogenix